Search Results for "CT P6 Celltrion"

18:02 EDT 31st March 2015 | BioPortfolio

Matching Channels

None

Matching News

Celltrion: Remsima could save UK, Italy and France $336m in five years

Celltrion has emphasised the savings Remsima ((inflizimab) could offer at a conference in Spain as partner Napp Pharmaceuticals prepares to extend the roll out of the Remicade biosimilar to the UK. 

Celltrion Announces that Remicade Biosimilar Could Save Up to $380 USD

Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease. Date:  ...

FDA delays meeting to discuss Remicade biosimilar

FDA's Arthritis Advisory Committee postponed a meeting that had been scheduled for March 17 to discuss a BLA from Celltrion Inc. (KOSDAQ:068270) for CT-P13, a biosimilar of Remicade infliximab from

Celltrion Announces that Remicade Biosimilar Could Save Up to $380 Million USD

Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease. Date:  ...

Celltrion launches Remicade biosimilar in Europe

Celltrion Inc. (KOSDAQ:068270) launched Remsima infliximab (CT-P13) in 12 European countries including Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sw...

Celltrion, Hospira avoid biosimilar traffic jam in U.S.

With an FDA advisory committee meeting approaching on March 17 for CT-P13 from Celltrion Inc. (KOSDAQ:068270) and Hospira Inc. (NYSE:HSP), the partners' U.S. interests are aligned thanks to an amended...

Celltrion To Launch Biosimilar Remicade in More European Countries

South Korea’s Celltrion has said it will begin selling Remsima, its biosimilar version of Johnson & Johnson‘s Remicade (infliximab) in 12 more European countries beginning February.

Crohn's disease Remsima could save up to €336m over five years, says Celltrion

The EMA-approved biosimilar monoclonal antibody Remsima, developed for Crohn's disease (CD), is likely to result in savings ranging from €76m to €336m over five years across, according to Celltrio...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement